Evidence map›Paper›PMID 26168232›Full record

ArticleThe Journal of investigative dermatology2015

Defining the Contribution of MC1R Physiological Ligands to ATR Phosphorylation at Ser435, a Predictor of DNA Repair in Melanocytes.

Stuart G Jarrett, Erin M Wolf Horrell, Mary C Boulanger, John A D'Orazio

Abstract read
In one paragraph

Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Genetic analysis of melanocortin 1 receptor red hair color variants in a Russian population of Eastern Siberia.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2018
    Article
  18. Mechanisms and prevention of UV-induced melanoma.Photodermatology, photoimmunology & photomedicine · 2018
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Stuart G JarrettMarkey Cancer Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Erin M Wolf HorrellMarkey Cancer Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA; Department of Physiology, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Mary C BoulangerDepartment of Dietetics and Human Nutrition, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
John A D'OrazioMarkey Cancer Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA; Department of Physiology, University of Kentucky College of Medicine, Lexington, Kentucky, USA; Department of Toxicology and Cancer Biology, University of Kentucky College of Medicine, Lexington, Kentucky, USA; Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA; Department of Pediatrics, University of Kentucky College of Medicine, Lexington, Kentucky, USA. Electronic address: jdorazio@uky.edu.
University of Kentucky · USMarkey Cancer Center · US

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI KATHLEEN L. O'CONNOR · 2013 to 2026
$38.3M
The role of Mc1r in melanocytic UV-induced DNA damage and repair responsesR01CA131075 · NCI · UNIVERSITY OF KENTUCKY · PI D'ORAZIO, JOHN A · 2010 to 2020
$3.3M
Interdisciplinary Research Training in Cancer BiologyT32CA165990 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers, KATHLEEN L. O'CONNOR · 2013 to 2026
$3.2M
NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA131075NCI NIH HHS T32 CA165990NCI NIH HHS T32CA165990
6 · The paper itself

Abstract

The melanocortin 1 receptor (MC1R), a GS-coupled receptor that signals through cAMP and protein kinase A (PKA), regulates pigmentation, adaptive tanning, and melanoma resistance. MC1R-cAMP signaling promotes PKA-mediated phosphorylation of ataxia telangiectasia and rad3-related (ATR) at Ser435 (ATR-pS435), a modification that enhances nucleotide excision repair (NER) by facilitating recruitment of the XPA protein to sites of UV-induced DNA damage. High-throughput methods were developed to quantify ATR-pS435, measure XPA-photodamage interactions, and assess NER function. We report that melanocyte-stimulating hormone (α-MSH) or ACTH induce ATR-pS435, enhance XPA's association with UV-damaged DNA and optimize melanocytic NER. In contrast, MC1R antagonists agouti signaling protein (ASIP) or human β-defensin 3 (HBD3) interfere with ATR-pS435 generation, impair the XPA-DNA interaction, and reduce DNA repair. Although ASIP and HBD3 each blocked α-MSH-mediated induction of the signaling pathway, only ASIP depleted basal ATR-pS435. Our findings confirm that ASIP diminishes agonist-independent MC1R basal signaling whereas HBD3 is a neutral MC1R antagonist that blocks activation by melanocortins. Furthermore, our data suggest that ATR-pS435 may be a useful biomarker for the DNA repair-deficient MC1R phenotype.

Indexed as

DNA RepairAgouti Signaling ProteinAtaxia Telangiectasia Mutated Proteinsbeta-DefensinsBiomarkersCells, CulturedCyclic AMP-Dependent Protein KinasesDNAHumansMelanocytesPhosphorylationReceptor, Melanocortin, Type 1SerineXeroderma Pigmentosum Group A ProteinAgouti Signaling ProteinAtaxia Telangiectasia Mutated ProteinsATR protein, humanbeta-DefensinsBiomarkersCyclic AMP-Dependent Protein KinasesDEFB103A protein, humanDNAReceptor, Melanocortin, Type 1SerineXeroderma Pigmentosum Group A ProteinXPA protein, human

Identifiers

PMID26168232
PMCPMC4648643
OpenAlexW874929073

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.